All In Biotech

Free tool

FAERS Monitor: Combivent Respimat

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021747 or its brand name (Combivent Respimat, Albuterol Sulfate, Ipratropium Bromide). Reports on generic versions are filed under their own applications.

Reports

2,765

Serious

1,506

54% of reports

Hospitalization

809

Death reported

214

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea449
  • off label use232
  • pneumonia195
  • drug ineffective171
  • fatigue170
  • cough168
  • headache151
  • death133
  • nausea132
  • pain121
  • asthma119
  • diarrhoea112
  • chronic obstructive pulmonary disease104
  • product dose omission issue104
  • malaise103

Reports by year received

View as table
YearReports
20114
20126
201340
201489
2015151
2016216
2017176
2018225
2019183
2020236
2021178
2022283
2023220
2024276
2025267
2026215

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,394 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic obstructive pulmonary diseaseSignal10415.212.61,365
asthmaSignal1198.06.7727
dyspnoeaSignal4496.05.51,933
pneumoniaSignal1954.64.0551
coughSignal1684.63.9469
product dose omission issueSignal1042.72.2110
off label useSignal2322.01.8123
headache1511.81.658
malaise1031.81.536
fatigue1701.71.446
pain1211.51.320
diarrhoea1121.31.19
nausea1321.31.18
death1331.21.03
drug ineffective1711.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.